- CELLMED Research GmbH1:
Austrian life science company founded in 2006
- CLINICAL COMPANY:
Phase I/IIa in ovarian cancer successfully completed with USD 20 million being raised currently for upcoming phase IIb
Patented unique double loaded dendritic cell therapy maximizing magnitude of efficacy directly activating both arms of the immune system without restrictions proven by striking phase I/IIa results
- Highly significant immune responses in 100% of patients treated
- Indication of zero material negative side effects
- Cancer recurrence delayed by >163% compared to control (interim data)
- Applicable to many indications other than ovarian cancer (current indication)
Patents are granted in the EU and Japan and pending in the US.
- SUPERIOR TARGETS:
Two universal tumor antigens Survivin & TERT, pivotal for development of most tumor types
- Maximize efficacy, minimize side effects
- Platform technology for a broad spectrum of therapeutic indications
Robust and of reproducible high quality with off the shelf antigens and potency release assay
Manufacturing automation and cost reduction concept ready for scale-up
GMP production technology, logistics, distribution and strong long-term management competence team
CELLMED is reshaping the future of cancer treatment by focusing on the clinical development of its lead product PROCURE®. By supporting the rise of personalized medicine and cellular immunotherapy CELLMED aims to provide a better treatment for patients.
Important criteria for dendritic cell therapy have been recently identified and established providing for the reduced risk and significant upside potential for CELLMED. Autologous cell therapy has almost no side effects but a very complicated mechanism of action. Many mistakes were made previously, resulting in ambiguous clinical data concerning dendritic cell vaccine efficacy as a treatment for cancer and notable corporate failures. Early clinical results suggest CELLMED's science has overcome these prior errors and its phase IIb protocols will provide stronger evidence of such.
CELLMED board of directors
- Gerhard Huber
- Gerhard Nidetzky
- Rudolf Zelenka
- Thomas Zivny